Screener
Capricor Therapeutics CAPR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | (5,121,709) | (896,007) |
| Payments for leasehold improvements | (921,752) | (244,279) |
| Payments for construction in progress | (4,703,521) | — |
| Net cash provided by (used in) investing activities | (154,641,596) | 23,890,673 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 1,470,659 | 50,354 |
| Net cash provided by financing activities | 1,470,659 | 50,354 |
| Net increase (decrease) in cash and cash equivalents | (182,425,828) | 17,507,507 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's investing cash flow?
- Capricor Therapeutics (CAPR) reported investing cash flow of -$154.64M in Q1 2026.
- How has Capricor Therapeutics's investing cash flow changed year-over-year?
- Capricor Therapeutics's investing cash flow decreased by 747.3% year-over-year, from $23.89M to -$154.64M.
- What is the long-term trend for Capricor Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Capricor Therapeutics's investing cash flow has grown at a 802.7% compound annual growth rate (CAGR), from -$1.2M to $97.48M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Capricor Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude